Duvelisib

Major

Duvelisib Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Duvelisib Abametapir Explained Increased exposure of CYP3A4 substrate Details Duvelisib Buprenorphine Belbuca Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Duvelisib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Duvelisib Simvastatin Flolipid Explained Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Acalabrutinib Calquence Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Avapritinib Ayvakit Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Duvelisib Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Duvelisib Avanafil Stendra Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Bedaquiline Sirturo Increased bedaquiline exposure Details Duvelisib Bosutinib Bosulif Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Brexpiprazole Rexulti Increased brexpiprazole exposure Details Duvelisib Budesonide Entocort Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Budesonide Nasal Spray Rhinocort Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Budesonide Oral Inhalation Pulmicort Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Cobimetinib Cotellic Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Duvelisib Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Duvelisib Dasatinib Phyrago Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Duvelisib Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Duvelisib Doxorubicin Adriamycin Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Duvelisib Encorafenib Braftovi Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Duvelisib Entrectinib Rozlytrek Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Duvelisib Everolimus Afinitor Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Felodipine Plendil® Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Fentanyl Transdermal Patch Duragesic® Increased fentaNYL exposure and an increased risk of prolonged opioid effects Details Duvelisib Finerenone Kerendia Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Ibrexafungerp Brexafemme Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Ibrutinib Imbruvica Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Ivabradine Corlanor Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Ketoconazole Topical Extina® Foam Increased duvelisib exposure Details Duvelisib Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Duvelisib Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Duvelisib Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse effects Details Duvelisib Lovastatin Altocor® Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Lumateperone Caplyta Increased lumateperone exposure and increased risk of lumateperone-related adverse reactions Details Duvelisib Lurasidone Latuda Increased exposure of sensitive CYP3A4 substrates and risk of toxicity Details Duvelisib Lurbinectedin Injection Zepzelca Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details